BridgeBio Q1 earnings: Attruby outperforms sales expectations, shares risenews2025-04-30T10:46:48+00:00April 30th, 2025|Endpoints News|
Pfizer’s Bourla projects confidence that tariffs will focus on US adversariesnews2025-04-29T19:04:58+00:00April 29th, 2025|Endpoints News|
How pharma is reacting to ‘Liberation Day’: Endpoints livestreamnews2025-04-29T18:27:36+00:00April 29th, 2025|Endpoints News|
FDA approves Abeona’s skin disease cell therapynews2025-04-29T15:06:37+00:00April 29th, 2025|Endpoints News|
With a new CEO, oligonucleotide biotech Creyon forges Eli Lilly partnershipnews2025-04-29T14:07:03+00:00April 29th, 2025|Endpoints News|
Hims and Novo Nordisk partner to offer discounted Wegovynews2025-04-29T11:30:07+00:00April 29th, 2025|Endpoints News|
AstraZeneca, Novartis execute ‘US for US’ strategy as pharma tariffs nearnews2025-04-29T11:22:54+00:00April 29th, 2025|Endpoints News|
Pfizer plans more cost cuts, expanding total savings to $7.7Bnews2025-04-29T11:17:44+00:00April 29th, 2025|Endpoints News|
AstraZeneca posts another Truqap study fail, says China import tax could triplenews2025-04-29T10:37:06+00:00April 29th, 2025|Endpoints News|
Novartis Q1 earnings: Company raises 2025 bar after beating sales expectationsnews2025-04-29T10:28:55+00:00April 29th, 2025|Endpoints News|
